ECSP099251A - Formulaciones farmacéuticas - Google Patents
Formulaciones farmacéuticasInfo
- Publication number
- ECSP099251A ECSP099251A EC2009009251A ECSP099251A ECSP099251A EC SP099251 A ECSP099251 A EC SP099251A EC 2009009251 A EC2009009251 A EC 2009009251A EC SP099251 A ECSP099251 A EC SP099251A EC SP099251 A ECSP099251 A EC SP099251A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical formulations
- active agent
- formulation
- release
- salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000012738 dissolution medium Substances 0.000 abstract 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 abstract 1
- 229960000701 fenofibric acid Drugs 0.000 abstract 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82925506P | 2006-10-12 | 2006-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099251A true ECSP099251A (es) | 2009-06-30 |
Family
ID=38961056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009251A ECSP099251A (es) | 2006-10-12 | 2009-04-13 | Formulaciones farmacéuticas |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2081563A1 (ko) |
JP (1) | JP2010506855A (ko) |
KR (1) | KR20090119959A (ko) |
CN (1) | CN101677981A (ko) |
AU (1) | AU2007307641A1 (ko) |
CA (1) | CA2672686A1 (ko) |
CO (1) | CO6160302A2 (ko) |
EA (1) | EA200900531A1 (ko) |
EC (1) | ECSP099251A (ko) |
IL (1) | IL198160A0 (ko) |
MX (1) | MX2009003815A (ko) |
SG (1) | SG175570A1 (ko) |
WO (1) | WO2008046052A1 (ko) |
ZA (1) | ZA200902488B (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102046153B (zh) * | 2008-05-30 | 2015-06-17 | Ucb医药有限公司 | 包含布立西坦的药物组合物 |
CN102304103A (zh) * | 2011-06-03 | 2012-01-04 | 郑州泰基鸿诺药物科技有限公司 | 一种非诺贝特酸盐、制备方法、药物组合物及应用 |
CN102659570B (zh) * | 2012-05-17 | 2014-05-28 | 安润医药科技(苏州)有限公司 | 二氟非诺贝特酸及其在药学上可接受的盐,以及它们的制备方法和应用 |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
CN107496397A (zh) * | 2016-06-14 | 2017-12-22 | 重庆安格龙翔医药科技有限公司 | 一种二甲双胍与非诺贝酸的复合物及其制剂 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7259186B2 (en) * | 2002-12-17 | 2007-08-21 | Abbott Laboratories | Salts of fenofibric acid and pharmaceutical formulations thereof |
EP1832285A1 (en) * | 2002-12-17 | 2007-09-12 | Abbott GmbH & Co. KG | Formulation comprising fenofibric acid or a physiologically acceptable salt thereof |
CN101480384A (zh) * | 2002-12-17 | 2009-07-15 | 阿伯特有限及两合公司 | 包含非诺贝酸、其生理可接受的盐或衍生物的制剂 |
EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
US20060280790A1 (en) * | 2005-04-08 | 2006-12-14 | Ju Tzuchi R | Pharmaceutical formulations |
-
2007
- 2007-10-12 WO PCT/US2007/081267 patent/WO2008046052A1/en active Application Filing
- 2007-10-12 JP JP2009532610A patent/JP2010506855A/ja active Pending
- 2007-10-12 SG SG2011070588A patent/SG175570A1/en unknown
- 2007-10-12 CA CA002672686A patent/CA2672686A1/en not_active Abandoned
- 2007-10-12 CN CN200780045748A patent/CN101677981A/zh active Pending
- 2007-10-12 EP EP07844238A patent/EP2081563A1/en not_active Withdrawn
- 2007-10-12 AU AU2007307641A patent/AU2007307641A1/en not_active Abandoned
- 2007-10-12 KR KR1020097007466A patent/KR20090119959A/ko not_active Application Discontinuation
- 2007-10-12 ZA ZA200902488A patent/ZA200902488B/xx unknown
- 2007-10-12 EA EA200900531A patent/EA200900531A1/ru unknown
- 2007-10-12 MX MX2009003815A patent/MX2009003815A/es not_active Application Discontinuation
-
2009
- 2009-04-13 EC EC2009009251A patent/ECSP099251A/es unknown
- 2009-04-13 CO CO09036680A patent/CO6160302A2/es unknown
- 2009-04-16 IL IL198160A patent/IL198160A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101677981A (zh) | 2010-03-24 |
JP2010506855A (ja) | 2010-03-04 |
MX2009003815A (es) | 2009-09-07 |
WO2008046052A1 (en) | 2008-04-17 |
IL198160A0 (en) | 2009-12-24 |
ZA200902488B (en) | 2010-10-27 |
EA200900531A1 (ru) | 2009-12-30 |
SG175570A1 (en) | 2011-11-28 |
KR20090119959A (ko) | 2009-11-23 |
CO6160302A2 (es) | 2010-05-20 |
AU2007307641A1 (en) | 2008-04-17 |
CA2672686A1 (en) | 2008-04-17 |
EP2081563A1 (en) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
ES2557303T3 (es) | Agente terapéutico para la estenosis del canal espinal | |
ES2528924T3 (es) | Formulación para el cuidado de heridas | |
NI201300054A (es) | Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas | |
CL2009001490A1 (es) | Sistema de suministro intrauterino que comprende un progestageno o una droga con actividad progestagenica y una sustancia terapeuticamente activa seleccionada de naproxeno, indometacina, ibuprofeno, acido mefenamico o flurbiprofeno, con la capacidad de evitar o suprimir el sangrado anormal y/o irregular. | |
CR10404A (es) | Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente | |
ECSP099251A (es) | Formulaciones farmacéuticas | |
AR058620A1 (es) | Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo | |
WO2009066146A3 (en) | Stable solutions of sparingly soluble actives | |
PE20091574A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
CO6140021A2 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
NI201100119A (es) | Composición de liberación pulsatil de sildenafil y proceso para prepararla. | |
ES2563632T3 (es) | Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa | |
PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno | |
BR112013006632A2 (pt) | composições e sistema de liberação de distribuição de droga aprimorados | |
ES2491565T3 (es) | Agente de transfección | |
CL2012001545A1 (es) | Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
UY29637A1 (es) | Formulación de liberación prolongada de principios activos de medicamentos | |
FR2937867B1 (fr) | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. | |
BRPI0608083A2 (pt) | composição compreendendo ocaperidona | |
AR070617A1 (es) | Formulacion farmaceutica que comprende oxabispidinas/236 |